Entry site neovascularization and vitreous cavity hemorrhage after diabetic vitrectomy. The predictive value of inner sclerostomy site ultrasonography
- PMID: 17976729
- DOI: 10.1016/j.ophtha.2007.08.034
Entry site neovascularization and vitreous cavity hemorrhage after diabetic vitrectomy. The predictive value of inner sclerostomy site ultrasonography
Abstract
Objective: To assess the incidence of neovascularization of the inner sclerostomy wound and occurrence of postoperative vitreous cavity hemorrhage (POVCH) after vitrectomy for proliferative diabetic retinopathy (PDR).
Design: Consecutive prospective longitudinal clinical study.
Participants: Seventy-three eyes (58 patients) undergoing primary vitrectomy for PDR.
Methods: Twenty-megahertz (MHz) high-resolution anterior segment ultrasonography was performed on all sclerostomy sites 2 months postoperatively and repeated at the time of any POVCH. The appearance of the inner sclerostomy wound was divided into 4 classes (normal, spheroidal, tent, and trapezoidal, representing entry site neovascularization). The occurrence, degree, and duration of POVCH and need for revision surgery with vitreous cavity washout (VCW) were recorded. Postoperative vitreous cavity hemorrhage was divided into 3 groups-namely, mild, moderate, and major.
Main outcome measures: Inner sclerostomy wound appearance on ultrasonography, degree and timing of POVCH, and need for VCW.
Results: There were 15 eyes in total with POVCH (20%): one patient had a persistent POVCH that required VCW. Fourteen other eyes (19%) had recurrent POVCH. Four (28%) of these 14 eyes with recurrent POVCH were classified as mild and 3 (21%) moderate: all cleared spontaneously with no further intervention needed. None of these had a trapezoidal image. Seven of the 14 eyes with recurrent POVCH were classified as major. Five of these 7 eyes had a trapezoidal image at 2 months postoperatively, and 4 required VCW (5.5% of total no. of eyes in study). All patients with a trapezoidal image experienced some degree of recurrent vitreous cavity hemorrhage (P = 0.0000024). The odds ratio was approximately 330:1. There was a significant correlation between the severity of POVCH and entry site appearance on ultrasound. In the first year of follow-up, all patients requiring VCW after recurrent POVCH had a trapezoidal image present at 2 months postoperatively (P = 0.009).
Conclusion: The appearance of a trapezoidal image on 20-MHz high-resolution anterior segment ultrasonography at a sclerostomy site after vitrectomy for PDR was highly correlated with the occurrence of nonclearing POVCH and need for VCW. Conversely, the absence of a trapezoidal image in patients with POVCH was associated with spontaneous hemorrhage clearance.
Similar articles
-
Entry site treatment to prevent late recurrent postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.Br J Ophthalmol. 2010 Sep;94(9):1219-25. doi: 10.1136/bjo.2009.170126. Epub 2009 Dec 2. Br J Ophthalmol. 2010. PMID: 19955203
-
Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings.Ophthalmology. 2004 Jun;111(6):1215-21. doi: 10.1016/j.ophtha.2003.08.043. Ophthalmology. 2004. PMID: 15177974
-
Endodiathermy plus photocoagulation as treatment of sclerotomy site vascularization secondary to pars plana vitrectomy for proliferative diabetic retinopathy.Retina. 2012 Jul;32(7):1310-5. doi: 10.1097/IAE.0b013e318236e7ef. Retina. 2012. PMID: 22466471
-
Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.Cochrane Database Syst Rev. 2023 May 31;5(5):CD008214. doi: 10.1002/14651858.CD008214.pub4. Cochrane Database Syst Rev. 2023. PMID: 37260074 Free PMC article. Review.
-
Management of proliferative diabetic retinopathy.Compr Ophthalmol Update. 2007 Sep-Oct;8(5):245-56. Compr Ophthalmol Update. 2007. PMID: 18201511 Review.
Cited by
-
Comparison of microinsicion vitrectomy and conventional 20-gauge vitrectomy for severe proliferative diabetic retinopathy.Jpn J Ophthalmol. 2015 Sep;59(5):288-94. doi: 10.1007/s10384-015-0396-y. Epub 2015 Jul 23. Jpn J Ophthalmol. 2015. PMID: 26202442 Clinical Trial.
-
Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis.Sci Rep. 2020 Nov 3;10(1):18880. doi: 10.1038/s41598-020-75896-8. Sci Rep. 2020. PMID: 33144606 Free PMC article.
-
A pilot study of viscoelastic agent to prevent recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy.BMC Ophthalmol. 2022 Dec 22;22(1):509. doi: 10.1186/s12886-022-02666-7. BMC Ophthalmol. 2022. PMID: 36550421 Free PMC article.
-
Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy.J Ophthalmol. 2016;2016:4108490. doi: 10.1155/2016/4108490. Epub 2016 May 16. J Ophthalmol. 2016. PMID: 27293875 Free PMC article.
-
The use of antivascular endothelial growth factor agents in the perioperative period in diabetic vitrectomy.Middle East Afr J Ophthalmol. 2012 Jan;19(1):83-7. doi: 10.4103/0974-9233.92120. Middle East Afr J Ophthalmol. 2012. PMID: 22346119 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical